Drug injury in the upper gastrointestinal tract: effects of alendronate.
Osteoporosis is a disease characterized by an increase in bone resorption and a decline in bone density, which leads to increased susceptibility to bone fractures. Long-term therapy is needed to increase bone mineral density and maintain bone strength. Safe and well-tolerated medical therapies are required for long-term maintenance. Alendronate, an oral bisphosphonate, has been used for treatment of osteoporosis since the mid 1990s; however, recent studies have suggested alendronate can have significant gastrointestinal side effects. Most data suggest that the risk of these effects is low and not significantly higher than with placebo but there are limited reports that suggest otherwise, in both clinical trials and animal studies. Alendronate continues to remain an important mainstay of osteoporosis therapy.
Department of Medicine, Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY 10029, USA.
Asma P
AP
Khapra
Suzanne
S
Rose
D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D004386:Duodenum / Q000293:injuries; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D005753:Gastric Mucosa / Q000187:drug effects* / Q000293:injuries; D006801:Humans; D023421:Models, Animal; D000068296:Risedronic Acid
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate